Recent Publications (2015-2021):

1)  Calais J, Czernin J, Thin P, Gartmann J, Nguyen K, Armstrong WR, Allen-Auerbach M, Quon A, Bahri S, Gupta P, Gardner L, Dahlbom M, He B, Esfandiari R, Ranganathan D, Hermann K, Eiber M, Fendler WP, Delpassand E.      Safety of PSMA-targeted molecular radioligand therapy with 177 Lu-PSMA-617: results from the prospective multicenter phase 2 trial RESIST-PC NCT03042312.  J Nucl Med. 2021 Jul 16:jnumed.121.262543. doi: 10.2967/jnumed.121.262543. Online ahead of print. PMID: 34272322

2)  Benz MR, Armstrong WR, Ceci F, Polverari G, Donahue TR, Wainberg ZA, Quon A, Auerbach M, Girgis MD, Herrmann K, Czernin J, Calais J.   18 F-FDG PET/CT imaging biomarkers for early and late evaluation of response to first-line chemotherapy in patients with pancreatic ductal adenocarcinoma.  J Nucl Med. 2021 Jul 16:jnumed.121.261952. doi: 10.2967/jnumed.121.261952. Online ahead of print. PMID: 34272317

3)  Gafita A, Calais J, Grogan TR, Hadaschik B, Wang H, Weber M, Sandhu S, Kratochwil C, Esfandiari R, Tauber R, Zeldin A, Rathke H, Armstrong WR, Robertson A, Thin P, D'Alessandria C, Rettig MB, Delpassand ES, Haberkorn U, Elashoff D, Herrmann K, Czernin J, Hofman MS, Fendler WP, Eiber M.   Nomograms to predict outcomes after 177 Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study.  Lancet Oncol. 2021 Jul 8:S1470-2045(21)00274-6. doi: 10.1016/S1470-2045(21)00274-6. Online ahead of print. PMID: 3424632

4)  Shuch B, Raman S, Calais J.    Reply to Alexa R. Meyer, Steven P. Rowe, and Nirmish Singla's Letter to the Editor re: Patrick D. McGillivray, Daiki Ueno, Aydin Pooli, et al. Distinguishing Benign Renal Tumors with an Oncocytic Gene Expression (ONEX) Classifier. Eur Urol 2021;79:107-11. Integrating 99m Tc-sestamibi and ONEX to Optimize Risk Stratification for Renal Masses.  Eur Urol. 2021 Jul;80(1):e22-e23. doi: 10.1016/j.eururo.2021.04.018. Epub 2021 Apr 30. PMID: 33941405

5)  Czernin J, Calais J.  177 Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine.  J Nucl Med. 2021 Jun 24:jnumed.121.262710. doi: 10.2967/jnumed.121.262710. Online ahead of print. PMID: 34168014 No abstract available.

6)  Giesel FL, Kratochwil C, Schlittenhardt J, Dendl K, Eiber M, Staudinger F, Kessler L, Fendler WP, Lindner T, Koerber SA, Cardinale J, Sennung D, Roehrich M, Debus J, Sathekge M, Haberkorn U, Calais J, Serfling S, Buck AL.  Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68 Ga-FAPI and 18 F-FDG PET/CT in cancer patients.  Eur J Nucl Med Mol Imaging. 2021 Jun 17. doi: 10.1007/s00259-021-05307-1. Online ahead of print. PMID: 34137945

7)  Valle L, Shabsovich D, de Meerleer G, Maurer T, Murphy DG, Nickols NG, Vapiwala N, Calais J, Kishan AU.   Use and Impact of Positron Emission Tomography/Computed Tomography Prior to Salvage Radiation Therapy in Men with Biochemical Recurrence After Radical Prostatectomy: A Scoping Review.  Eur Urol Oncol. 2021 Jun;4(3):339-355. doi: 10.1016/j.euo.2021.01.007. Epub 2021 Feb 24. PMID: 33637464

8)  Gafita A, Wang H, Robertson A, Armstrong WR, Zaum R, Weber M, Yagubbayli F, Kratochwil C, Grogan TR, Nguyen K, Navarro F, Esfandiari R, Rauscher I, Menze B, Elashoff D, Delpassand ES, Herrmann K, Czernin J, Hofman MS, Calais J, Fendler WP, Eiber M.  Tumor sink effect in 68 Ga-PSMA-11 PET: Myth or Reality?  J Nucl Med. 2021 May 28:jnumed.121.261906. doi: 10.2967/jnumed.121.261906. Online ahead of print. PMID: 34049987

9)  Calais J, Gafita A, Eiber MR, Armstrong WR, Gartmann J, Thin P, Nguyen K, Lok V, Gosa L, Grogan T, Esfandiari R, Ranganathan D, Allen-Auerbach MS, Quon A, Bahri S, Gupta P, Gardner L, Slavik R, Dahlbom M, Herrmann K, Delpassand ES, Fendler WP, Czernin J.  Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177 Lu-PSMA-617 for metastatic Castration-reSISTant Prostate Cancer (RESIST-PC): Efficacy results of the UCLA cohort.  J Nucl Med. 2021 May 20:jnumed.121.261982. doi: 10.2967/jnumed.121.261982. Online ahead of print. PMID: 34016732

10)  Calais J, Zhu S, Hirmas N, Eiber M, Hadaschik B, Stuschke M, Herrmann K, Czernin J, Kishan AU, Nickols NG, Elashoff D, Fendler WP. Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol.  BMC Cancer. 2021 May 7;21(1):512. doi: 10.1186/s12885-021-08026-w. PMID: 33962579

11)  Hotta M, Sonni I, Benz MR, Gafita A, Bahri S, Shuch BM, Yu R, Liu ST, Czernin J, Calais J.  68 Ga-FAPI-46 and 18 F-FDG PET/CT in a patient with immune-related thyroiditis induced by immune checkpoint inhibitors.  Eur J Nucl Med Mol Imaging. 2021 Apr 29. doi: 10.1007/s00259-021-05373-5. Online ahead of print. PMID: 33914106

12)  Lawhn-Heath C, Salavati A, Behr SC, Rowe SP, Calais J, Fendler WP, Eiber M, Emmett L, Hofman MS, Hope TA. Prostate-specific Membrane Antigen PET in Prostate Cancer.                  Radiology. 2021 May;299(2):248-260. doi: 10.1148/radiol.2021202771. Epub 2021 Mar 30. PMID: 33787338

13)  Hope TA, Graves CE, Calais J, Ehman E, Johnson GB, Thompson D, Aslam M, Duh QY, Gosnell J, Shen W, Roman S, Sosa JA, Kluijfhout W, Seib CS, Villanueva-Meyer J, Pampaloni MH, Suh I.   Accuracy of 18 F-fluorocholine PET for the detection of parathyroid adenomas: prospective single center study.  J Nucl Med. 2021 Mar 5:jnumed.120.256735. doi: 10.2967/jnumed.120.256735. Online ahead of print. PMID: 33674400

14)  Fendler WP, Calais J.   We Can Make a Difference: Investigator-driven Prostate-specific Membrane Antigen Radiotheranostics for Prostate Cancer.  Eur Urol Focus. 2021 Mar;7(2):227-228. doi: 10.1016/j.euf.2021.02.002. Epub 2021 Feb 18. PMID: 33612416

15)  Calais J, Armstrong WR, Kishan AU, Booker KM, Hope TA, Fendler WP, Elashoff D, Nickols NG, Czernin J.  Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome.  Eur Urol Focus. 2021 Mar;7(2):238-240. doi: 10.1016/j.euf.2020.12.009. Epub 2020 Dec 30. PMID: 33386288

16)  Ma TM, Gafita A, Shabsovich D, Juarez J, Grogan TR, Thin P, Armstrong W, Sonni I, Nguyen K, Lok V, Reiter RE, Rettig MB, Steinberg ML, Kupelian PA, Yang DD, Muralidhar V, Chu C, Feng F, Savjani R, Deng J, Parikh NR, Nickols NG, Elashoff D, Czernin J, Calais J, Kishan AU.  Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging.  Eur Urol Oncol. 2021 Feb 15:S2588-9311(21)00030-4. doi: 10.1016/j.euo.2021.01.006. Online ahead of print. PMID: 33602654

17)  Hope TA, Calais J.   PSMA-targeted radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancer.  Lancet. 2021 Feb 27;397(10276):768-769. doi: 10.1016/S0140-6736(21)00349-4. Epub 2021 Feb 11. PMID: 33581799

18)  Sartor O, Hope TA, Calais J, Fendler WP. Oliver Sartor Talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler About FDA Approval of PSMA.  J Nucl Med. 2021 Feb;62(2):146-148. doi: 10.2967/jnumed.120.261834. PMID: 33468543

19)  Armstrong WR, Gafita A, Zhu S, Thin P, Nguyen K, Alano RM, Lira S, Booker K, Gardner L, Grogan T, Elashoff D, Allen-Auerbach MS, Dahlbom MS, Czernin J, Calais J.  The impact of monosodium glutamate on 68 Ga-PSMA-11 biodistribution in men with prostate cancer: a prospective randomized, controlled, imaging study.  J Nucl Med. 2021 Jan 28:jnumed.120.257931. doi: 10.2967/jnumed.120.257931. Online ahead of print. PMID: 33509974

20)  Calais J, Armstrong WR, Kishan AU, Booker KM, Hope TA, Fendler WP, Elashoff D, Nickols NG, Czernin J.  Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome.   Eur Urol Focus. 2020 Dec 29:S2405-4569(20)30311-4. doi: 10.1016/j.euf.2020.12.009.  PMID: 33386288

21)  Valle LF, Lehrer EJ, Markovic D, Elashoff D, Levin-Epstein R, Karnes RJ, Reiter RE, Rettig M, Calais J, Nickols NG, Dess RT, Spratt DE, Steinberg ML, Nguyen PL, Davis BJ, Zaorsky NG, Kishan AU.   A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER).  Eur Urol. 2020 Dec 10:S0302-2838(20)30874-5. doi: 10.1016/j.eururo.2020.11.010. Online ahead of print. PMID: 33309278

22)    Parikh NR, Tsai S, Bennett C, Lewis M, Sadeghi A, Lorentz W, Cheung M, Garraway I, Aronson W, Kishan AU, Bahri S, Vahidi K, Calais J, Ishimitsu D, Rettig M, Nickols NG, Jafari L.   The Impact of 18 F-DCFPyL PET-CT Imaging on Initial Staging, Radiation, and Systemic Therapy Treatment Recommendations for Veterans With Aggressive Prostate Cancer.  Adv Radiat Oncol. 2020 Sep 9;5(6):1364-1369. doi: 10.1016/j.adro.2020.08.014. eCollection 2020 Nov-Dec. PMID: 33305100

23)  Urbán S, Meyer C, Dahlbom M, Farkas I, Sipka G, Besenyi Z, Czernin J, Calais J, Pávics L.  Radiation dosimetry of Tc99m-PSMA I&S: a single-center prospective study.  J Nucl Med. 2020 Dec 4:jnumed.120.253476. doi: 10.2967/jnumed.120.253476. Online ahead of print. PMID: 33277398

24)  Stuparu AD, Capri JR, Meyer C, Le TM, Evans-Axelsson SL, Current K, Lennox M, Mona CE, Fendler WP, Calais J, Eiber M, Dahlbom M, Czernin J, Radu CG, Lückerath K, Slavik R.  Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer.  J Nucl Med. 2020 Dec 4:jnumed.120.256263. doi: 10.2967/jnumed.120.256263. Online ahead of print. PMID: 33277393

25)  Polverari G, Ceci F, Passera R, Crane J, Du L, Li G, Fanti S, Bernthal N, Eilber FC, Allen-Auerbach M, Czernin J, Calais J, Federman N.  [ 18 F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial.   EJNMMI Res. 2020 Oct 15;10(1):122. doi: 10.1186/s13550-020-00715-0. PMID: 33063147

26)  Villemain O, Baranger J, Jalal Z, Lam C, Calais J, Pernot M, Cifra B, Friedberg MK, Mertens L.  Non-invasive imaging techniques to assess myocardial perfusion.  Expert Rev Med Devices. 2020 Nov;17(11):1133-1144. doi: 10.1080/17434440.2020.1834844. Epub 2020 Oct 22. PMID: 33044100

27) Lenis AT, Pooli A, Lec PM, Sadun TY, Johnson DC, Lebacle C, Fendler WP, Eiber M, Czernin J, Reiter RE, Calais J.  Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.  Eur Urol Oncol. 2020 Sep 18:S2588-9311(20)30139-5. doi: 10.1016/j.euo.2020.08.012. Online ahead of print. PMID: 32958451

28)  Miyahira AK, Pienta KJ, Babich JW, Bander NH, Calais J, Choyke P, Hofman MS, Larson SM, Lin FI, Morris MJ, Pomper MG, Sandhu S, Scher HI, Tagawa ST, Williams S, Soule HR.  Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting.  Prostate. 2020 Nov;80(15):1273-1296. doi: 10.1002/pros.24056. Epub 2020 Aug 31. PMID: 32865839

29)  Fendler WP, Calais J, Eiber M, Simko JP, Kurhanewicz J, Santos RD, Feng FY, Reiter RE, Rettig MB, Nickols NG, Kishan AU; PSMA PET Reader Group, Slavik R, Carroll PR, Lawhn-Heath C, Herrmann K, Czernin J, Hope TA. False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial.  Eur J Nucl Med Mol Imaging. 2020 Aug 17. doi: 10.1007/s00259-020-04945-1. Online ahead of print. PMID: 32808077

30)   Calais J, Mona CE. Will FAPI PET/CT Replace FDG PET/CT in the Next Decade? Point-An Important Diagnostic, Phenotypic, and Biomarker Role.  AJR Am J Roentgenol. 2020 Dec 23:1-2. doi: 10.2214/AJR.20.24302. Online ahead of print. PMID: 32755205

31)  Hayrapetian A, Girgis MD, Yanagawa J, French SW, Schelbert HR, Auerbach MS, Czernin J, Calais J.  Incidental Detection of Elastofibroma Dorsi With 68Ga-FAPI-46 and 18F-FDG PET/CT in a Patient With Esophageal Cancer.  Clin Nucl Med. 2021 Feb 1;46(2):e86-e87. doi: 10.1097/RLU.0000000000003218. PMID: 32701818

32)  Sonni I, Lee-Felker S, Memarzadeh S, Quinn MM, Mona CE, Lückerath K, Czernin J, Calais J. 68 Ga-FAPi-46 diffuse bilateral breast uptake in a patient with cervical cancer after hormonal stimulation.  Eur J Nucl Med Mol Imaging. 2020 Jul 10. doi: 10.1007/s00259-020-04947-z. Online ahead of print. PMID: 32651662

33)  Czernin J, Calais J.  Nuclear Medicine, Molecular Imaging, and Theranostics: The Future Is Bright.  J Nucl Med Technol. 2020 Jun;48(Suppl 1):82S-83S. PMID: 32605963

34)  Truffault B, Bourhis D, Chaput A, Calais J, Robin P, Le Pennec R, Lucia F, Leclère JC, Gujral DM, Vera P, Salaün PY, Schick U, Abgral R.  Correlation Between FDG Hotspots on Pre-radiotherapy PET/CT and Areas of HNSCC Local Relapse: Impact of Treatment Position and Images Registration Method.  Front Med (Lausanne). 2020 Jun 4;7:218. doi: 10.3389/fmed.2020.00218. eCollection 2020. PMID: 32582727

35)  Gafita A, Fendler WP, Hui W, Sandhu S, Weber M, Esfandiari R, Calais J, Rauscher I, Rathke H, Tauber R, Delpassand ES, Weber WA, Herrmann K, Czernin J, Eiber M, Hofman MS.  Efficacy and Safety of 177 Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study.  Eur Urol. 2020 Aug;78(2):148-154. doi: 10.1016/j.eururo.2020.05.004. Epub 2020 Jun 10. PMID: 32532512

36)  Sonni I, Caron J, Kishan AU, Muthusamy VR, Calais J.  PSMA Expression in the Neovasculature Associated With Rectal Adenocarcinoma: A Potential Stromal Target for Nuclear Theranostics.  Clin Nucl Med. 2020 Jul;45(7):e309-e310. doi: 10.1097/RLU.0000000000003066. PMID: 32404709

37)  Tan N, Oyoyo U, Bavadian N, Ferguson N, Mukkamala A, Calais J, Davenport MS. PSMA-targeted Radiotracers versus 18 F Fluciclovine for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis.  Radiology. 2020 Jul;296(1):44-55. doi: 10.1148/radiol.2020191689. Epub 2020 May 12. PMID: 32396045

38)  Fendler WP, Ferdinandus J, Czernin J, Eiber M, Flavell RR, Behr SC, Wu IK, Lawhn-Heath C, Pampaloni MH, Reiter RE, Rettig MB, Gartmann J, Murthy V, Slavik R, Carroll PR, Herrmann K, Calais J, Hope TA.  Impact of 68 Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial.  J Nucl Med. 2020 Dec;61(12):1793-1799. doi: 10.2967/jnumed.120.242180. Epub 2020 May 1. PMID: 32358094

39)  Calais J.  FAP: The Next Billion Dollar Nuclear Theranostics Target?  J Nucl Med. 2020 Feb;61(2):163-165. doi: 10.2967/jnumed.119.241232. Epub 2020 Jan 10. PMID: 31924719

40)  Sonni I, Eiber M, Fendler WP, Alano RM, Vangala SS, Kishan AU, Nickols N, Rettig MB, Reiter RE, Czernin J, Calais J.   Impact of 68 Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study.  J Nucl Med. 2020 Aug;61(8):1153-1160. doi: 10.2967/jnumed.119.237602. Epub 2020 Jan 10. PMID: 31924715

41)  Meyer C, Dahlbom M, Lindner T, Vauclin S, Mona C, Slavik R, Czernin J, Haberkorn U, Calais J. Radiation Dosimetry and Biodistribution of 68 Ga-FAPI-46 PET Imaging in Cancer Patients.  J Nucl Med. 2020 Aug;61(8):1171-1177. doi: 10.2967/jnumed.119.236786. Epub 2019 Dec 13. PMID: 31836685

42) Farolfi A, Ilhan H, Gafita A, Calais J, Barbato F, Weber M, Afshar-Oromieh A, Spohn F, Wetter A, Rischpler C, Hadaschik B, Pianori D, Fanti S, Haberkorn U, Eiber M, Herrmann K, Fendler WP.  Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET.  J Nucl Med. 2020 Jul;61(7):1037-1042. doi: 10.2967/jnumed.119.235374. Epub 2019 Dec 5. PMID: 31806773

43)  Gafita A, Calais J, Franz C, Rauscher I, Wang H, Roberstson A, Czernin J, Weber WA, Eiber M. Evaluation of SUV normalized by lean body mass (SUL) in 68 Ga-PSMA11 PET/CT: a bi-centric analysis.    EJNMMI Res. 2019 Dec 2;9(1):103. doi: 10.1186/s13550-019-0572-z. PMID: 31792771  

44)  Czernin J, Allen-Auerbach M, Calais J.  Of Sheep and Wolves: Curtailing Coverage for Essential Imaging Tests Based on Flawed Use and Cost Arguments.   J Nucl Med. 2019 Dec;60(12):1657-1658. doi: 10.2967/jnumed.119.237636. PMID: 31792126

45)  Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Fendler WP, Czernin J.   What is the best PET target for early biochemical recurrence of prostate cancer?-Authors' reply.  Lancet Oncol. 2019 Nov;20(11):e609-e610. doi: 10.1016/S1470-2045(19)30654-0. PMID: 31674314

46)  Pomykala KL, Czernin J, Grogan TR, Armstrong WR, Williams J, Calais J.  Total-Body 68 Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines.  J Nucl Med. 2020 Mar;61(3):405-411. doi: 10.2967/jnumed.119.230318. Epub 2019 Sep 20. PMID: 31541035

47)  Farolfi A, Gafita A, Calais J, Eiber M, Afshar-Oromieh A, Spohn F, Barbato F, Weber M, Ilhan H, Cervati V, Wetter A, Hadaschik B, Briganti A, Walz J, Pianori D, Fanti S, Haberkorn U, Herrmann K, Fendler WP.  Reply by Authors.  J Urol. 2019 Dec;202(6):1181. doi: 10.1097/01.JU.0000582680.86998.12. Epub 2019 Sep 16. PMID: 31524577

48)  Fendler WP, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, Ilhan H, Saad F, Small EJ, Smith MR, Perez PM, Hope TA, Rauscher I, Londhe A, Lopez-Gitlitz A, Cheng S, Maurer T, Herrmann K, Eiber M, Hadaschik B.  Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.  Clin Cancer Res. 2019 Dec 15;25(24):7448-7454. doi: 10.1158/1078-0432.CCR-19-1050. Epub 2019 Sep 11. PMID: 31511295

49)  Czernin J, Sonni I, Razmaria A, Calais J.  The Future of Nuclear Medicine as an Independent Specialty.   J Nucl Med. 2019 Sep;60(Suppl 2):3S-12S. doi: 10.2967/jnumed.118.220558. PMID: 31481589

50)  Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J.  18 F-fluciclovine PET-CT and 68 Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.  Lancet Oncol. 2019 Sep;20(9):1286-1294. doi: 10.1016/S1470-2045(19)30415-2. Epub 2019 Jul 30. PMID: 31375469

51)  Rauscher I, Fendler WP, Hope TA, Quon A, Nekolla SG, Calais J, Richter A, Haller B, Herrmann K, Weber WA, Czernin J, Eiber M.  Can the Injected Dose Be Reduced in 68 Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection?  J Nucl Med. 2020 Feb;61(2):189-193. doi: 10.2967/jnumed.119.227207. Epub 2019 Jul 19. PMID: 31324710

52)  Calais J, Touati A, Grall N, Laouénan C, Benali K, Mahida B, Vigne J, Hyafil F, Iung B, Duval X, Lepage L, Le Guludec D, Rouzet F.  Diagnostic Impact of 18 F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and White Blood Cell SPECT/Computed Tomography in Patients With Suspected Cardiac Implantable Electronic Device Chronic Infection.  Circ Cardiovasc Imaging. 2019 Jul;12(7):e007188. doi: 10.1161/CIRCIMAGING.117.007188. Epub 2019 Jul 11. PMID: 31291779

53) Farolfi A, Gafita A, Calais J, Eiber M, Afshar-Oromieh A, Spohn F, Barbato F, Weber M, Ilhan H, Cervati V, Wetter A, Hadaschik B, Briganti A, Walz J, Pianori D, Fanti S, Haberkorn U, Herrmann K, Fendler WP. 68 Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study.  J Urol. 2019 Dec;202(6):1174-1181. doi: 10.1097/JU.0000000000000417. Epub 2019 Jun 24. PMID: 31233369

54)  Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA.  Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.   JAMA Oncol. 2019 Jun 1;5(6):856-863. doi: 10.1001/jamaoncol.2019.0096. PMID: 30920593

55)  Hope TA, Calais J, Zhang L, Dieckmann W, Millo C.    111 In-Pentetreotide Scintigraphy Versus 68 Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden.  J Nucl Med. 2019 Sep;60(9):1266-1269. doi: 10.2967/jnumed.118.223016. Epub 2019 Mar 8. PMID: 30850506

56)  Tan N, Bavadian N, Calais J, Oyoyo U, Kim J, Turkbey IB, Mena E, Davenport MS. Imaging of Prostate Specific Membrane Antigen Targeted Radiotracers for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis.  J Urol. 2019 Aug;202(2):231-240. doi: 10.1097/JU.0000000000000198. Epub 2019 Jul 8. PMID: 30829130

57)  Lubin DJ, Holden SB, Rettig MB, Reiter RE, King CR, Lee JM, Wallace DW, Calais J.  Prostate Cancer Pulmonary Metastasis Presenting as a Ground-Glass Pulmonary Nodule on 68Ga-PSMA-11 PET/CT.  Clin Nucl Med. 2019 May;44(5):e353-e356. doi: 10.1097/RLU.0000000000002499. PMID: 30789399

58)  Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG.  Correction to: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].   BMC Cancer. 2019 Jan 21;19(1):97. doi: 10.1186/s12885-019-5297-x. PMID: 30665383

59)  Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG. Randomized prospective phase III trial of 68 Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT.  BMC Cancer. 2019 Jan 7;19(1):18. doi: 10.1186/s12885-018-5200-1. PMID: 30616601

60) Razmaria A, Calais J, Czernin J. Delivering Radionuclide Therapies Requires Extensive Training and Competence: Send a Firm Message to the NRC and Your Representatives.  J Nucl Med. 2019 Jan;60(1):1-2. PMID: 30602593 

61)  Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP, Carroll PR.  Metaanalysis of 68 Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology.   J Nucl Med. 2019 Jun;60(6):786-793. doi: 10.2967/jnumed.118.219501. Epub 2018 Dec 7. PMID: 30530831

62)  Lückerath K, Wei L, Fendler WP, Evans-Axelsson S, Stuparu AD, Slavik R, Mona CE, Calais J, Rettig M, Reiter RE, Herrmann K, Radu CG, Czernin J, Eiber M. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer.  EJNMMI Res. 2018 Oct 29;8(1):96. doi: 10.1186/s13550-018-0451-z. PMID: 30374743

63)  Polverari G, Ceci F, Allen-Auerbach M, Gupta P, Fishbein MC, Reiter RE, Lee JM, Hope TA, Carroll RM, Czernin J, Calais J.   Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by 68 Ga-PSMA-11 PET/CT.  Clin Genitourin Cancer. 2019 Feb;17(1):e53-e55. doi: 10.1016/j.clgc.2018.09.003. Epub 2018 Sep 7. PMID: 30293922

64)  Ceci F, Polverari G, Calais J, Castellucci P.  The influence of PSA flare in mCRPC patients treated with alpha-emitting radiopharmaceuticals.  Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2253-2255. doi: 10.1007/s00259-018-4162-5. PMID: 30232540

65)  Calais J, Kishan AU, Cao M, Fendler WP, Eiber M, Herrmann K, Ceci F, Reiter RE, Rettig MB, Hegde JV, Shaverdian N, King CR, Steinberg ML, Czernin J, Nickols NG.  Potential Impact of 68 Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer.  J Nucl Med. 2018 Nov;59(11):1714-1721. doi: 10.2967/jnumed.118.209387. Epub 2018 Apr 13. PMID: 29653978

66)  Lückerath K, Stuparu AD, Wei L, Kim W, Radu CG, Mona CE, Calais J, Rettig M, Reiter RE, Czernin J, Slavik R, Herrmann K, Eiber M, Fendler WP.  Detection Threshold and Reproducibility of 68 Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer.  J Nucl Med. 2018 Sep;59(9):1392-1397. doi: 10.2967/jnumed.118.207704. Epub 2018 Mar 30. PMID: 29602819

67)  Calais J, Fendler WP, Herrmann K, Eiber M, Ceci F.  Reply: Comparison of 68 Ga-PSMA-11 and 18 F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Prospective Trial Is on Its Way.  J Nucl Med. 2018 May;59(5):861. doi: 10.2967/jnumed.118.209965. Epub 2018 Mar 1. PMID: 29496985

68)  Calais J, Cao M, Nickols NG.  The Utility of PET/CT in the Planning of External Radiation Therapy for Prostate Cancer.  J Nucl Med. 2018 Apr;59(4):557-567. doi: 10.2967/jnumed.117.196444. Epub 2018 Jan 4. PMID: 29301928

69)  Zeitouni M, Calais J, Ghodbane W, Ou P, Sannier A, Bouleti C. A Cardiac Myxoma With Intense Metabolic Activity.  Can J Cardiol. 2018 Jan;34(1):92.e11-92.e12. doi: 10.1016/j.cjca.2017.10.010. Epub 2017 Oct 19. PMID: 29275890

70)  Calais J, Fendler WP, Herrmann K, Eiber M, Ceci F.  Comparison of 68 Ga-PSMA-11 and 18 F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence.         J Nucl Med. 2018 May;59(5):789-794. doi: 10.2967/jnumed.117.203257. Epub 2017 Dec 14. PMID: 29242404

71)  Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, Reiter RE, Rettig MB, Marks LS, Ahlering TE, Huynh LM, Slavik R, Gupta P, Quon A, Allen-Auerbach MS, Czernin J, Herrmann K.  Impact of 68 Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence.  J Nucl Med. 2018 Mar;59(3):434-441. doi: 10.2967/jnumed.117.202945. Epub 2017 Dec 14. PMID: 29242398

72)  Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King CR, Steinberg ML, Rauscher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG.  68 Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.  J Nucl Med. 2018 Feb;59(2):230-237. doi: 10.2967/jnumed.117.201749. Epub 2017 Nov 9. PMID: 29123013

73)  Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, Hope T, Reiter R, Maurer T, Weber WA, Fendler WP. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT.  J Nucl Med. 2018 Mar;59(3):469-478. doi: 10.2967/jnumed.117.198119. Epub 2017 Nov 9. PMID: 29123012

74)  Eiber M, Fendler WP, Rowe SP, Calais J, Hofman MS, Maurer T, Schwarzenboeck SM, Kratowchil C, Herrmann K, Giesel FL.  Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy.  J Nucl Med. 2017 Sep;58(Suppl 2):67S-76S. doi: 10.2967/jnumed.116.186767. PMID: 28864615

75)  Calais J, Czernin J, Eiber M, Fendler WP, Gartmann J, Heaney AP, Hendifar AE, Pisegna JR, Hecht JR, Wolin EM, Slavik R, Gupta P, Quon A, Schiepers C, Allen-Auerbach MS, Herrmann K.  Most of the Intended Management Changes After 68 Ga-DOTATATE PET/CT Are Implemented.  J Nucl Med. 2017 Nov;58(11):1793-1796. doi: 10.2967/jnumed.117.192450. Epub 2017 May 4. PMID: 28473600

76)  Fendler WP, Calais J, Allen-Auerbach M, Bluemel C, Eberhardt N, Emmett L, Gupta P, Hartenbach M, Hope TA, Okamoto S, Pfob CH, Pöppel TD, Rischpler C, Schwarzenböck S, Stebner V, Unterrainer M, Zacho HD, Maurer T, Gratzke C, Crispin A, Czernin J, Herrmann K, Eiber M. 68 Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study.  J Nucl Med. 2017 Oct;58(10):1617-1623. doi: 10.2967/jnumed.117.190827. Epub 2017 Apr 13. PMID: 28408531    

77)  Chaput A, Calais J, Robin P, Thureau S, Bourhis D, Modzelewski R, Schick U, Vera P, Salaün PY, Abgral R.  Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.  Head Neck. 2017 Jun;39(6):1155-1165. doi: 10.1002/hed.24738. Epub 2017 Mar 6. PMID: 28263422

78)  Calais J, Pasi N, Nguyen V, Hyafil F.  Mycotic aneurysm in a pulmonary artery detected with 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging.   Eur Heart J. 2017 Dec 7;38(46):3474. doi: 10.1093/eurheartj/ehw571. PMID: 28057774

79)  Calais J, Edet-Sanson A, Gaucher S, Vera P, Le Cloirec J.  Tc-99m-HMPAO-Labeled Leukocyte SPECT/CT in Pediatrics: Detecting Candida albicans Tricuspid Endocarditis.  Nucl Med Mol Imaging. 2015 Dec;49(4):333-4. doi: 10.1007/s13139-015-0333-5. Epub 2015 Apr 15. PMID: 26550057

80)  Calais J, Lussato D, Merlet P.  Reply to "18F-Choline PET-CT in the Management of Lung Cancer and Mucinous Tumors?"  J Thorac Oncol. 2015 Jun;10(6):e49-50. doi: 10.1097/JTO.0000000000000527. PMID: 26001152

81)  Calais J, Dubray B, Nkhali L, Thureau S, Lemarignier C, Modzelewski R, Gardin I, Di Fiore F, Michel P, Vera P.  High FDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer.  Eur J Nucl Med Mol Imaging. 2015 May;42(6):858-67. doi: 10.1007/s00259-015-3004-y. Epub 2015 Feb 14. PMID: 25680400

82)  Calais J, Thureau S, Dubray B, Modzelewski R, Thiberville L, Gardin I, Vera P.  Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.  J Nucl Med. 2015 Feb;56(2):196-203. doi: 10.2967/jnumed.114.144253. Epub 2015 Jan 8. PMID: 25572091